Presentation is loading. Please wait.

Presentation is loading. Please wait.

Forest plot illustrating risk ratio of stent thrombosis

Published byOsvaldo Silveira Modified over 5 years ago

Similar presentations

Presentation on theme: "Forest plot illustrating risk ratio of stent thrombosis"— Presentation transcript:

1 Forest plot illustrating risk ratio of stent thrombosis
Forest plot illustrating risk ratio of stent thrombosis. AF, atrial fibrillation; DOAC, advent of direct oral anticoagulants; PCI, percutaneous coronary interventions; VKAs, vitamin K antagonists. Forest plot illustrating risk ratio of stent thrombosis. AF, atrial fibrillation; DOAC, advent of direct oral anticoagulants; PCI, percutaneous coronary interventions; VKAs, vitamin K antagonists. Natale Daniele Brunetti et al. Open Heart 2018;5:e000785 ©2018 by British Cardiovascular Society

Download ppt "Forest plot illustrating risk ratio of stent thrombosis"

Similar presentations

Date of download: 6/27/2016 Copyright © The American College of Cardiology. All rights reserved. From: Use and Outcomes of Triple Therapy Among Older Patients.

Date of download: 6/27/2016 Copyright © The American College of Cardiology. All rights reserved. From: Use and Outcomes of Triple Therapy Among Older Patients.
An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin k antagonist.

An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin k antagonist.
Volume 149, Issue 6, Pages (June 2016)

Volume 149, Issue 6, Pages (June 2016)
An approach to using risk scores for stroke and bleeding in clinical practice. An approach to using risk scores for stroke and bleeding in clinical practice.

An approach to using risk scores for stroke and bleeding in clinical practice. An approach to using risk scores for stroke and bleeding in clinical practice.
Duration of triple therapy in patients requiring oral anticoagulation after drug-eluting stent implantation (ISAR-TRIPLE Trial) - press conference - Katrin.

Duration of triple therapy in patients requiring oral anticoagulation after drug-eluting stent implantation (ISAR-TRIPLE Trial) - press conference - Katrin.
Safety and Effectiveness of Direct Oral Anticoagulants Versus Vitamin K Antagonists: Pilot Implementation of a Near‐Real‐Time Monitoring Program in Italy.

Safety and Effectiveness of Direct Oral Anticoagulants Versus Vitamin K Antagonists: Pilot Implementation of a Near‐Real‐Time Monitoring Program in Italy.
by Kueiyu Joshua Lin, Daniel E. Singer, Robert J

by Kueiyu Joshua Lin, Daniel E. Singer, Robert J
2016 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation  Laurent Macle, MD, John Cairns, MD, Kori.

2016 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation  Laurent Macle, MD, John Cairns, MD, Kori.
Barriers to Oral Anticoagulant Use for Stroke Prevention in AF

Barriers to Oral Anticoagulant Use for Stroke Prevention in AF
Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio
Volume 15, Issue 1, Pages (January 2018)

Volume 15, Issue 1, Pages (January 2018)
FAERS death cases (all years) for NOACs versus warfarin.

FAERS death cases (all years) for NOACs versus warfarin.
Forest plot of the HRs for DOACs vs warfarin for (A) new or recurrent VTE and (B) major bleeding based on the published subanalyses of the patients with.

Forest plot of the HRs for DOACs vs warfarin for (A) new or recurrent VTE and (B) major bleeding based on the published subanalyses of the patients with.
Effect of PCI on 1-year risk of all-cause mortality and major cardiovascular outcomes. CABG, coronary artery bypass grafting; CI, confidence interval (bars);

Effect of PCI on 1-year risk of all-cause mortality and major cardiovascular outcomes. CABG, coronary artery bypass grafting; CI, confidence interval (bars);
Coronary revascularisation rate (total 5

Coronary revascularisation rate (total 5
Non-vitamin k antagonist oral anticoagulants in a European primary care physician survey by Claudio Cimminiello, Robert Hatala, Sami Pakarinen, Hernan.

Non-vitamin k antagonist oral anticoagulants in a European primary care physician survey by Claudio Cimminiello, Robert Hatala, Sami Pakarinen, Hernan.
Non-vitamin k antagonist oral anticoagulants in a European primary care physician survey by Claudio Cimminiello, Robert Hatala, Sami Pakarinen, Hernan.

Non-vitamin k antagonist oral anticoagulants in a European primary care physician survey by Claudio Cimminiello, Robert Hatala, Sami Pakarinen, Hernan.
Any and definite stent thrombosis (ST) and in-device late lumen loss (LLL) with bioresorbable vascular scaffold (BVS) versus drug-eluting stent (DES) in.

Any and definite stent thrombosis (ST) and in-device late lumen loss (LLL) with bioresorbable vascular scaffold (BVS) versus drug-eluting stent (DES) in.
Forest plot of risk ratio with its 95% CI for the incidence of contrast-induced nephropathy among patient taking statin versus control based on renal impairment.

Forest plot of risk ratio with its 95% CI for the incidence of contrast-induced nephropathy among patient taking statin versus control based on renal impairment.
Tornado diagram of one-way deterministic sensitivity analysis.

Tornado diagram of one-way deterministic sensitivity analysis.

Similar presentations

Ads by Google